A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)

NCT00000836 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

300

Enrollment

NIH

Sponsor class

Conditions

Cytomegalovirus Retinitis
HIV Infections

Interventions

DRUG: Sevirumab

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)